Browsing Tag

actinium-225

POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial

Eli Pacheco Jan 13, 2023 0

INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access…

Health

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy &…

Eli Pacheco Aug 19, 2022 0

In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at…

Health

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

Eli Pacheco May 5, 2022 0

INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access…